Therefore, targeting MGST1 expression to modulate ferroptosis might enhance the efficacy of KRASG12D inhibitor MRTX1133 and inhibit tumor progression, which could be a promising strategy for PDAC patients with KRASG12D mutations. The gene discussed is MGST1; the disease is neoplasm.